Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD

NCT00157976 is registered in ClinicalTrials.gov with Miravant Pharmaceuticals as lead sponsor.

NCT NCT00157976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00157976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
Lead sponsor
Miravant Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2005
Completion date
Not reported
Enrollment
660
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration